Literature DB >> 14734727

CpG-DNA aided cross-priming by cross-presenting B cells.

Antje Heit1, Katharina M Huster, Frank Schmitz, Matthias Schiemann, Dirk H Busch, Hermann Wagner.   

Abstract

Covalent linkage of immunostimulatory CpG-DNA to OVA (CpG-OVA complex) results in CpG-DNA-aided cross-presentation of OVA by dendritic cells (DCs). In this study, we analyzed the thesis that CpG-OVA complexes may be cross-presented by B cells to route internalized Ag into the class I MHC presentation pathway. First, we describe that conjugation of CpG-DNA to OVA enhances up to 40-fold internalization of OVA by B cells, which in turn generate the CD8 T cell epitope SIINFEKL complexed to MHC class I, albeit less efficiently than DCs. Furthermore, upon internalization, CpG-DNA conjugated to OVA stimulates B cells to up-regulate costimulatory molecules and cytokines including IL-12. Adoptive transfer of CpG-OVA complex-loaded wild-type B cells cross-primes naive CD8 T cells both in wild-type mice and in MyD88-deficient mice. Overall, these findings disclose attributes of B cells, including cross-presentation of exogenous Ag and cross-priming of naive CD8 T cells that hitherto have been considered as hallmarks restricted to DCs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14734727     DOI: 10.4049/jimmunol.172.3.1501

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

Review 1.  Cross-presentation: dendritic cells and macrophages bite off more than they can chew!

Authors:  Sven Brode; Paul A Macary
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

2.  Encapsulating immunostimulatory CpG oligonucleotides in listeriolysin O-liposomes promotes a Th1-type response and CTL activity.

Authors:  Chasity D Andrews; Myung-Sook Huh; Kathryn Patton; Debbie Higgins; Gary Van Nest; Gary Ott; Kyung-Dall Lee
Journal:  Mol Pharm       Date:  2012-04-06       Impact factor: 4.939

Review 3.  Cross-priming in health and disease.

Authors:  Christian Kurts; Bruce W S Robinson; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2010-06       Impact factor: 53.106

4.  CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2.

Authors:  Adriano F S Araújo; Bruna C G de Alencar; José Ronnie C Vasconcelos; Meire I Hiyane; Cláudio R F Marinho; Marcus L O Penido; Silvia B Boscardin; Daniel F Hoft; Ricardo T Gazzinelli; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

5.  Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles.

Authors:  Hong Shen; Anne L Ackerman; Virginia Cody; Alessandra Giodini; Ella R Hinson; Peter Cresswell; Richard L Edelson; W Mark Saltzman; Douglas J Hanlon
Journal:  Immunology       Date:  2006-01       Impact factor: 7.397

Review 6.  Antigen cross-presentation: extending recent laboratory findings to therapeutic intervention.

Authors:  T W H Flinsenberg; E B Compeer; J J Boelens; M Boes
Journal:  Clin Exp Immunol       Date:  2011-05-11       Impact factor: 4.330

7.  Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1.

Authors:  Chuanlin Ding; Li Wang; Jose Marroquin; Jun Yan
Journal:  Blood       Date:  2008-07-31       Impact factor: 22.113

8.  CpG-enhanced CD8+ T-cell responses to peptide immunization are severely inhibited by B cells.

Authors:  Michael G Overstreet; Helen Freyberger; Ian A Cockburn; Yun-Chi Chen; Sze-Wah Tse; Fidel Zavala
Journal:  Eur J Immunol       Date:  2010-01       Impact factor: 5.532

9.  Delivery of Exogenous Antigens to Induce Cytotoxic CD8+ T Lymphocyte Responses.

Authors:  Julia Kim; Vandana Gambhir; Attiya Alatery; Sameh Basta
Journal:  J Biomed Biotechnol       Date:  2010-05-23

10.  Induction of protective cytotoxic T-cell responses by a B-cell-based cellular vaccine requires stable expression of antigen.

Authors:  S Guo; J Xu; W Denning; Z Hel
Journal:  Gene Ther       Date:  2009-07-30       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.